Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Meropenem and imipenem/cilastatin were compared in an open, randomised prospective multicentre study in the treatment of acute exacerbations of severe chronic obstructive pulmonary disease in hospitalised patients. One-hundred-and-seventy-three patients were enrolled; 164 were evaluable for clinical efficacy and 98 for bacteriological efficacy, with 144 pathogens isolated. The predominant pathogens were Haemophilus influenzae (n = 30), Streptococcus pneumoniae (18), Staphylococcus aureus (12), Pseudomonas aeruginosa (11), Moraxella catarrhalis (8), other Gram-negative bacteria (Neisseria, Klebsiella, Proteus, and Enterobacter spp.) (53) and other Gram-positive bacteria (12). A single bacterial pathogen was identified in 61 patients, whereas two bacterial pathogens were isolated in 31 patients and three in six patients. The clinical response at the end of treatment was very high in both groups with a satisfactory outcome (cured or improved) in 97.6% of the meropenem patients and in 96.3% of the imipenem/cilastatin patients; at follow-up the rates were 89.1% and 89.8%, respectively. The bacterial success (eradication or presumed eradication) was 88.2% in the meropenem group and 89.4% in the comparator group. Nausea or vomiting were reported more frequently in patients treated with imipenem/cilastatin, whereas in the meropenem group an increase in aminotransferases was reported. One patient treated with imipenem/cilastatin was withdrawn from the study due to seizures. Meropenem and imipenem/cilastatin were highly effective for the treatment of severe bacterial exacerbations of chronic bronchitis but meropenem was better tolerated.
Department for Chest and Infectious Diseases, City Hospital Zehlendorf, Berlin, Germany.
J
J
Hamacher
F
F
Vogel
J
J
Lichey
F V
FV
Kohl
K
K
Diwok
H
H
Wendel
H
H
Lode
D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology*; D015780:Carbapenems / Q000627:therapeutic use*; D015377:Cilastatin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006760:Hospitalization; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000150:complications*; D000077731:Meropenem; D011446:Prospective Studies; D013845:Thienamycins / Q000627:therapeutic use*; D016896:Treatment Outcome
D015780:Carbapenems; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D000077731:Meropenem